Summit Therapeutics Share Discussion Threads

[waterloo01] 29/3/2018 13:12

OT. I applaud Trump for going after Amazon. I've long felt they are turning into an evil business, destroying everything in their path and leaving waste grounds. Why governments didn't switch to a sales based tax on these sorts of companies is a scandal, as it's depleted the public coffers, laid waste to the retail environment and destroyed some industries and replaced them with an aggressive buyer (Amazon squeeze suppliers) and provide low skilled, soul destroying jobs and no community.

Why it hasn't been subject of a monopolies commission is remarkable in that it hasn't happened.

Happy Easter.

[football] 28/3/2018 20:54

Snap and me toooooo

[waterloo01] 28/3/2018 18:49

Super gonorrhoea

Dr Gwenda Hughes, from Public Health England, said: "This is the first time a case has displayed such high-level resistance to both of these drugs and to most other commonly used antibiotics."


RNS 2 weeks ago:

"In early testing, the new series of antibiotic compounds has been shown
to have high potency against strains of gonorrhoea with no development
of resistance to date. The series of antibiotic compounds was identified
using Summit's recently acquired technology platform. Summit intends to
select a candidate from the gonorrhoea programme for entering into IND
enabling studies in the second half of 2018. The Company believes the
identified series of antibiotic compounds has the potential to produce a
new front-line therapy for gonorrhoea. "

[chrisatrdg] 28/3/2018 12:18

My thoughts too & maybe the contents were made known to this weeks 'new investors' hence their speed to take up this weeks share offer.Exciting times.

[waterloo01] 28/3/2018 12:11

Rolling out Dame Kay and the whole team. Interesting that's both poster and oral and 1.15m session, so they will do doubt be adding to the data already presented.

[chrisatrdg] 28/3/2018 12:07

RNS Today

Summit Therapeutics Selected for Emerging Science Presentation at the 2018 AAN Annual Meeting



Edit: Maybe will learn a little more & support for yesterdays additional funding.

[hugus maximus] 27/3/2018 19:30

Perfectly sir ... many thanks!

[hugus maximus] 27/3/2018 16:46

I'd still prefer Summit to be in control of their complete DMD pipeline at the end of this period, rather than accept some silly bargain bin offer from SRPT ... am hoping that the majority of shareholders would agree. (Edit i.e. post 48 wk results)

Afternoon Waterloo ... can you explain for the viewers "lack of response re MRI measures" and "RNS supporting that view" ... pretty please?

[waterloo01] 27/3/2018 15:55

Agree. Done and dusted. No more cash calls this year and the potential of ETZ going for approvals on the 48wk results. I was postulating yesterday about the lack of response re MRI measures, and think the RNS today supports that view.

No champers this AGM but will the company look the same (or exist as an independent entity) by the end of 2018?

[gclark] 27/3/2018 14:13

That's a pretty good result for the placing, at a small discount to the share price. It gives the company the money for the developments.

[hugus maximus] 27/3/2018 13:23

The placement doesn't seem to have harmed the share price too much so far. SMMT BB's in the USA seem to see it as a positive move toward approval being financed, (though of course also like the fact that it's a UK fund raise!)

[football] 27/3/2018 08:28

Suppose I'm like most here clicked on the newsfeed and you see another big placing and think FFS not again! But then you look at the price of the placing and it's only 4-5p below the bid price which isn't that bad at all.
As Hyper Al says it looks like someone wanted in pretty quick and maybe before any drug results hit the market, this placing would have taken a few days so the price probably was about £1.80 when agreed so they probably paid the full price to get in quick rather than spreading it over a couple weeks and maybe forcing the price up higher and costing them more or any positive test results which would of made the share price a lot higher.



gla








Summit Therapeutics launches placing to raise £15mln to advance its treatment for Duchenne Muscular Dystrophy

07:40 27 Mar 2018
The company said it expects to use the placing’s net proceeds to accelerate preparatory activities for a placebo-controlled clinical trial for DMD treatment ezutromid

Read more

[anusol] 27/3/2018 07:44

Why are my apostrophes coming out as question marks?

[anusol] 27/3/2018 07:43

Placing always feel like a negative thing (and usually true!) but at 180p it's a fairly efficient way to source additional funds especially as interest rates are finally on an upwards trajectory (slow one).See it's not being underwritten so is that confidence or just an acknowledgement that they are just grabbing what they can whilst there's some strength in the SP

[waterloo01] 27/3/2018 07:32

Pesky placings but it does confirm the idea that they might be applying for accelerated approval based on 48wk data!

RDZ has slipped to 1st Q 2019.

[hugus maximus] 26/3/2018 22:55

I wonder at what point our politicians will actually engage with this issue and make it worth while for big pharma to make enough noughts behind the pound signs to get out of bed in the morning?

The big pharmaceutical guns are clearly waiting for world health organisations to start subsidising enough of their business risk before stumping up their own investment money.

It's written about far and wide that there's not enough potential profit yet in the offing, to bother with such matters as the well being of the human race!
(Was that a rant? - ed.)

[football] 26/3/2018 20:46

Global antibiotic consumption soars feeding spread of UK 'super-bugs'

[hugus maximus] 26/3/2018 13:28

Good thought Waterloo. So perhaps an RNS at some point soon to announce a pathway through FDA approval via MRI work, which has recently shown to be the most definitively useful "end point"?

I still don't believe the market understands the potential in Summit's Utrophin Modulation or indeed sees quite how close it could be to success.

Perhaps an agreement with the FDA over a different "end point", and resulting access to market before P3 will wake things up? That's certainly a game changer that's possible before we even get as far as 48 wks results.

[hugus maximus] 23/3/2018 15:43

Sarepta however, still have the cavalry charging behind them!

Speaking of which their NASDAQ discussions are full of this today (see below) ... 'not sure what difference this might make for the DMD community or a drug like Ezutromid? But perhaps that's what's keeping the cavalry charge in full swing with You Know Who?